Feature

Research Reports

Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib

08/19/2020

&quot

Henry J Henk, PhD

Lena E Winestone, MD, MSHP

Jennifer J Wilkes, MD, MSCE

Pamela Morin, MBA

Shasank Chennupati, PharmD, MPH

David R Doody, MS

Eric J Chow, MD, MPH

Gary H Lyman, MD, MPH&quot

Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...

...

08/19/2020

Journal of Clinical Pathways

From the Field

Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices

08/19/2020

Stacey W McCullough, PharmD

David Blaisdell, BA

Jonathan K Kish, PhD, MPH

JaLyna Laney, RN

Tom Valuck, MD, JD

Natalie Dickson, MD

Jesus G Berdeja, MD

Jeffrey F Patton, MD

Ronda Copher, PhD

Annette Powers, PharmD, MBA

Abstract: It is widely recognized that the quality of medical care received in the United States is suboptimal, and poor-quality care may contribute to disparities in cancer incidence and mortality. While...

...

08/19/2020

Journal of Clinical Pathways

From the Field

Insights Gained From a Pilot Study Investigating Early Survivorship Care Interventions

06/17/2020

Deborah Christensen, MSN, APRN

Bonita S Agee, PhD

Cheryl Bellomo, MSN, RN, OCN

Abstract: Intermountain Healthcare, a Utah-based, not-for-profit organization, co-sponsored a pilot study to evaluate potential benefits of early survivorship care by offering a treatment summary and survivorship...

...

06/17/2020

Journal of Clinical Pathways

Perspectives

COVID-19 Pandemic Vindicates the ISPOR Value Flower

06/17/2020

Jason Shafrin, PhD

Kathy Lang, PhD

Ross Maclean, MD

Abstract: What is the right price for a new treatment for COVID-19? One common approach—which is frequently used worldwide and in the United States by the Institute of Clinical and Economic Review—measures treatment...

...

06/17/2020

Journal of Clinical Pathways

Research Reports

The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis

05/19/2020

Abdalla Aly, PhD

Courtney Johnson, MPH

Yunes Doleh, MPH, PharmD

Viktor Chirikov, MS, PhD

Marc Botteman, MSc

Rahul Shenolikar, MS, PhD

Arif Hussain, MD

Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...

...

05/19/2020

Journal of Clinical Pathways

From the Field

Enhancing the Electronic Health Record to Improve the Quality of Breast Cancer Care in Eastern North Carolina

05/19/2020

Helen M Johnson, MD

Lauren E Geisel, MD

Andrew Weil, MD

Mahvish Muzaffar, MD

Nasreen A Vohra, MD

Phyllis DeAntonio, RN

Jan H Wong, MD

Abstract: Eastern North Carolina (ENC) is home to a rural population that suffers from disparities in breast cancer outcomes. It has been demonstrated that evidence-based clinical pathways can improve quality of...

...

05/19/2020

Journal of Clinical Pathways

Research Reports

The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology

04/21/2020

Ajeet Gajra, MD, FACP1

Chadi Nabhan, MD, MBA2

Andrew J Klink, PhD, MPH1

Ting-Chun Yeh, PhD1

Bela Bapat, MS3

Yolaine J Smith, PhD1

Bruce A Feinberg, DO1

Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...

...

04/21/2020

Journal of Clinical Pathways

From the Field

Design and Integration of Predictive Modeling in the Oncology Clinical Setting to Reduce Readmissions

04/21/2020

Kelsey Jarrold, MSISE1

Raghad Alkhawaldeh, PhD-c2

Karen Sites, MSN, RN, OCN, CCM3

Tammy Brown, MSN, RN, NEA-BC, OCN3

Courtney Crannell, DNP, MSN, RN-BC, OCN4

Vernon Alders, MHCDS, MBA, MSW1

Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...

...

04/21/2020

Journal of Clinical Pathways

Research Reports

Real-World Analysis of Outpatient Rasburicase to Prevent and Manage Tumor Lysis Syndrome in Newly Diagnosed Adults With Leukemia or Lymphoma

03/16/2020

Scott C Howard, MD, MSc

Alex R Cockerham, PharmD, RPh, MSc

Edward Drea, PharmD

Yvonne Barnes, DNP, RN

Michael Ryan

William Irish, PhD

Lucio Gordan, MD

Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...

...

03/16/2020

Journal of Clinical Pathways

Perspectives

The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study

03/16/2020

Andrew Hertler, MD, FACP

William A Flood, MD, MS

Ray Page, DO, PhD, FACOI, FASCO

Barry Brooks, MD

Steve L D’Amato, BSPharm, BCOP

Michael Kolodziej, MD

Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...

...

03/16/2020

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products